共 69 条
[1]
Lomma C(2021)Male breast cancer in Australia Asia Pac J Clin Oncol 17 e57-e62
[2]
Chan A(2020)Management of male breast cancer: ASCO guideline J Clin Oncol 38 1849-1863
[3]
Chih H(2018)Breast cancer in men N Engl J Med 378 2311-2320
[4]
Reid C(2021)Treatment of male breast cancer: meta-analysis of real-world evidence Br J Surg 108 1034-1042
[5]
Peter W(2021)NCCN Guidelines(R) Insights: Breast Cancer, Version 4.2021 J Natl Compr Canc Netw 19 484-493
[6]
Hassett MJ(2021)Clinical outcomes with Abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience J Natl Compr Cancer Netw. 21 25-1212
[7]
Somerfield MR(2019)CDK 4/6 inhibitors in breast cancer: current controversies and future directions Curr Oncol Rep 26 1208-125
[8]
Baker ER(2020)FDA approval summary: palbociclib for male patients with metastatic breast cancer Clin Cancer Res 12 120-2025
[9]
Cardoso F(2020)Male patient with metastatic stage IV breast cancer achieves complete remission on second line Abemaciclib, Fulvestrant and Leuprolide: a case report Mol Clin Oncol 82 P1-18-29-1495
[10]
Kansal KJ(2021)Male patients with HR+/HER2—advanced breast cancer receiving Palbociclib in a real-world setting: patient characteristics, treatment patterns, and outcomes in the POLARIS study Cancer Res 124 2018-8